NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIG

NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company’s common stock will trade under the ticker symbol SIGYD for 20 business days and subsequently revert to trading under its historic symbol SIGY on Feb. 29, 2024,” the company stated in the press release. The company also reported that its post-split CUSIP number for its common stock is 82674U205. According to Sigyn Therapeutics, 1,221,043 of its common shares were issued and outstanding at the close of trading on Jan. 31, 2024.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://nnw.fm/SIGY

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer